Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments?
![](/46/pdcnewsitem/03/42/78/FX35G630gDGkRno.jpg)
Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the market for its treatment. Further, popular drugs such as Almita and Avastin are nearing their patent expiry in 2015 and 2017 respectively. As such, the lung cancer therapeutics market offers vast potential that drug manufacturers are vying to tap into. Approximately 130 drugs for the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are in various stages of development and are expected to hit the market by 2020.
New analysis from Frost & Sullivan, A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market, finds that many niche, as well as established drug manufacturers, are devoting resources to the R&D of targeted therapies, which are likely to replace conventional medicine within the next 10 years. The US FDA, European Medicines Agency, FDA Japan and National Institute for Health and Care Excellence are also encouraging investments in targeted therapies.
The lung cancer therapeutics market is characterized by intense competition, especially among large pharmaceutical firms such as Merck, AstraZeneca, Eli Lilly and Bristol-Myers Squibb (BMS). In particular, AstraZeneca, Roche, Merck and BMS are in a close race to produce effective drugs targeted at PD-L1 pathway and anaplastic lymphoma kinase (ALK). BMS has already launched Opdivo (Nivolumab) in Japan, becoming the first company to introduce its drug candidate for the PD-L1 pathway.
“However, the development of targeted therapies for mutations such as kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor (HER) and BRAF is yet to pick up pace,” said Frost & Sullivan Healthcare Research Analyst Sumedha Pareek. “The market is also in need of cost-efficient drugs.”
The cost of late-stage cancer treatment is approximately 43% higher than the costs involved in early-stage cancer detection. Employing combined-modality therapies may help in cutting down these expenses.
“For instance, the first-line treatment for NSCLC is typically chemotherapy,” explained Pareek. “This might change with the introduction of Necitumumab by Eli Lilly, at present in the third phase of clinical trials in the US. In combination with chemotherapy, Necitumumab has the potential to be the first targeted therapy used for cost-effective first-line treatment.”
Overall, close collaboration among pharmaceutical companies, translational scientists and university research groups will continue to aid the much-needed identification of new, economical targeted therapies for lung cancer.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance